Mae mynediad at y dogfennau caffael yn gyfyngedig. Gellir cael rhagor o wybodaeth yn:
Rhif y Lot 1
II.2.1) Teitl
Etanercept
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Etanercept to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per line to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Supply chain
/ Pwysoliad: 5
Price
/ Pwysoliad:
95
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 46 271 726.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 24
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 2
II.2.1) Teitl
Infliximab IV
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Infliximab IV to NHS Scotland. The authority intends to award this Lot as a unranked multi-supplier per line to a maximum of five (5) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Supply chain
/ Pwysoliad: 5
Price
/ Pwysoliad:
95
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 18 784 068.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 24
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 3
II.2.1) Teitl
Infliximab Subcutaneous
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Infliximab Subcutaneous to NHS Scotland. The authority intends to award this lot as a single supplier framework per line. Full details of Goods and volumes can be found within the ITT documents.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Supply chain
/ Pwysoliad: 5
Price
/ Pwysoliad:
95
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 307 680.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 24
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 4
II.2.1) Teitl
Adalimumab
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Adalimumab to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per line to a maximum of six (6) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Supply chain
/ Pwysoliad: 5
Price
/ Pwysoliad:
95
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 60 835 914.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 24
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 5
II.2.1) Teitl
Methotrexate (50 mg per 1 ml Concentration) Pre-filled Self Injection Device
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of methotrexate (50 mg per 1 ml concentration) pre-filled self injection device to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per lot to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Supply chain
/ Pwysoliad: 5
Price
/ Pwysoliad:
95
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 18 947 932.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 24
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 6
II.2.1) Teitl
Methotrexate (50 mg per 1 ml Concentration) Pre-filled Syringes
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of Methotrexate (50 mg per 1 ml concentration) pre-filled syringes to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per lot to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Supply Chain
/ Pwysoliad: 5
Price
/ Pwysoliad:
95
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 482 418.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 24
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 7
II.2.1) Teitl
Methotrexate (25 mg per 1 ml Concentration) Pre-filled Self Injection Device
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of methotrexate (25 mg per 1 ml concentration) pre-filled self injection device to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per lot to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Supply chain
/ Pwysoliad: 5
Price
/ Pwysoliad:
95
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 298 263.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 24
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Rhif y Lot 8
II.2.1) Teitl
Methotrexate (25 mg per 1 ml Concentration) Pre-filled Syringes
II.2.2) Cod(au) CPV ychwanegol
33600000
II.2.3) Man cyflawni
Cod NUTS:
UKM
Prif safle neu fan cyflawni:
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any integrated joint boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
II.2.4) Disgrifiad o’r caffaeliad
Supply of methotrexate (25 mg per 1 ml concentration) pre-filled syringes to NHS Scotland. The authority intends to award this lot as a unranked multi-supplier framework per lot to a maximum of three (3) framework participants. Full details of goods and volumes can be found within the ITT documents.
II.2.5) Meini prawf dyfarnu
Maen prawf isod:
Maes prawf ansawdd: Supply chain
/ Pwysoliad: 5
Price
/ Pwysoliad:
95
II.2.6) Gwerth amcangyfrifedig
Gwerth heb gynnwys TAW: 465 862.00 GBP
II.2.7) Hyd y contract, y cytundeb fframwaith neu’r system brynu ddynamig
Hyd mewn misoedd: 24
Gall y contract hwn gael ei adnewyddu: Ydy
Disgrifiad o’r adnewyddiadau:
This framework includes the option(s) to extend for up to a total period of twenty four (24) months upon giving not less than three (3) months written notice, such notice to expire no later than the date the framework agreement is due to expire.
II.2.9) Gwybodaeth am y cyfyngiadau ar nifer yr ymgeiswyr a gaiff eu gwahodd
II.2.10) Gwybodaeth am amrywiadau
Derbynnir amrywiadau:
Na
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
III.1.3) Gallu technegol a phroffesiynol
Rhestr a disgrifiad byr o’r meini prawf dethol:
(a) Potential framework participants must be able to demonstrate that a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA will be in place for all tendered goods prior to the start date of the framework agreement.
(b) Potential framework participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered goods must comply with the MHRA best practice guidance on labelling and packaging and the National Patient Safety Agency (‘NPSA’) guidelines on packaging and labelling on pack design.
Lefel(au) gofynnol y safonau sydd eu hangen:
(a) Confirmation that a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA will be in place for all tendered goods prior to the start of the framework agreement should be included in the qualification envelope of the ITT under the technical and professional ability: quality control.
(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the qualification envelope of the ITT under the quality assurance schemes.
(c) Confirmation that samples for tendered goods will be supplied upon request to ensure compliance with the MHRA best practice guidance on labelling and packaging and the National Patient Safety Agency (‘NPSA’) guidelines on packaging and labelling on pack design. Confirmation of sample provision should be provided in the qualification envelope of the ITT under technical and professional ability: products.
The estimated values referred to in Section II.I.5) and all lots cover the initial twenty four (24) month duration and the maximum twenty four (24)-month extension period.
The buyer is using PCS-Tender to conduct this ITT exercise. The project code is 17106. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343
The contracting authority does not intend to include a sub-contract clause as part of community benefits (as per Section 25 of the Procurement Reform (Scotland) Act 2014) in this contract for the following reason:
It is not envisaged that sub-contractors will be utilised in delivery of this framework agreement.
The contracting authority does not intend to include any community benefit requirements in this contract for the following reason:
No community benefits will be deliverable through the award of this framework agreement.